Project A3: Notch signaling as a novel target of AML/ETO

Principal Investigators

 Prof. Dr. Franz Oswald
Department of Internal Medicine I
Ulm University
Albert-Einstein-Allee 23
89081 Ulm
Phone: 0731-500-44544
franz.oswald(at)uni-ulm.de

Curriculum Vitae

Prof. Dr. Hartmut Geiger
Institute for Molecular Medicine
Ulm University
Life Sciences Building N27
James-Franck-Ring 11c
89081 Ulm
Phone: 0731-50-26700
hartmut.geiger(at)uni-ulm.de

 Curriculum Vitae

Summary

AML1-ETO9a (AE9a) is an alternatively spliced isoform of the t(8;21) fusion protein and is clinically associated with poor prognosis. In a retroviral bone marrow transplantation model we con-firmed the high oncogenic potential of AE9a. However, in a conditional mouse model of AE9a expression in hematopoietic cells leukemia induction failed. This discrepancy points towards the requirement of additional events (deregulated expression of genes/protein, signals from the niche, etc.) in AE9a-mediated leukemogen-esis in our mouse model. These factors might represent novel promising targets to inhibit leukemia develop-ment. Retroviral insertion mutagenesis will be applied in the genomic mouse model followed by validation of potential candidates using molecular biological/biochemical approaches as well as via comparative analyses of clinical gene expression data sets.

For a current list of project-related publications, please go to this page